Outlook Aims To Remedy FDA Concerns On Ophthalmic Bevacizumab

Requests Type A Meeting With FDA Following Complete Response Letter

 
• By Dave Wallace

Outlook Therapeutics has confirmed that it has requested a Type A meeting with the FDA, to discuss issues raised in a complete response letter received in connection to the firm’s application for an ophthalmic formulation of bevacizumab.

Eye data binary
Outlook is looking to resolve issues with its BLA • Source: Shutterstock

More from Biosimilars

More from Products